Theravance Biopharma, Inc. (TBPH)
17.08
+0.01
(+0.06%)
USD |
NASDAQ |
Sep 03, 13:40
Theravance Biopharma Research and Development Expense (Annual) : 35.91M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 35.91M |
| December 31, 2024 | 36.04M |
| December 31, 2023 | 38.72M |
| December 31, 2022 | 60.79M |
| December 31, 2021 | 190.16M |
| December 31, 2020 | 257.65M |
| December 31, 2019 | 215.95M |
| December 31, 2018 | 201.35M |
| Date | Value |
|---|---|
| December 31, 2017 | 173.89M |
| December 31, 2016 | 141.71M |
| December 31, 2015 | 129.16M |
| December 31, 2014 | 168.52M |
| December 31, 2013 | 120.58M |
| December 31, 2012 | 114.00M |
| December 31, 2011 | 98.85M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Zymeworks, Inc. | 137.00M |
| Viatris, Inc. | 952.50M |
| Ocular Therapeutix, Inc. | 197.10M |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Corcept Therapeutics, Inc. | 254.91M |